MARKET OUTLOOK

The introduction of additional Crohn’s disease (CD) agents has shifted—and will continue to shift—market dynamics. The newer non-TNF biologics (Takeda’s Entyvio and Janssen’s Stelara) intensify the competition among branded agents, while additional entries and the expanded use of less-expensive biosimilar TNF-α inhibitors provide physicians—and payers—with the potential for more-cost-effective alternatives. The anticipated entry of emerging agents with novel MOAs (e.g., Jak inhibitors) and/or more-convenient delivery formulations (e.g., oral formulations) will further impact the evolving treatment landscape and add greater complexity to market access.

QUESTIONS ANSWERED

  • How do reimbursement terms for CD biologics vary across the EU5? How do payers regulate use of these premium-priced agents?
  • How do prescribing patterns for key CD therapies differ between and within EU5 countries, and to what extent does payer policy impact uptake?
  • How has the launch of biosimilars altered payer preferences and mandates, and what has the actual impact of biosimilar availability been on physician prescribing?
  • What key market access challenges do emerging CD agents face? What lessons have been learned, and what market access levers can drug developers take advantage of to optimize the positioning of their products?

PRODUCT DESCRIPTION

Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

GEOGRAPHY

EU5: France, Germany, Italy, Spain, United Kingdom

PRIMARY RESEARCH

Survey of 250

gastroenterologists across the EU5 (50 per country)

Interviews with 10 EU5 payers (2 per country)

KEY DRUGS COVERED

Humira, Remicade, Cimzia, Entyvio, Stelara, biosimilar infliximab, ozanimod, Alofisel, etrolizumab, risankizumab

CONTENT HIGHLIGHTS

  • Actionable recommendations to optimize market access
  • Market access success and stumbles
  • Market access roadblocks
  • Reimbursement dynamics
  • The impact of pricing and reimbursement, policy, and coverage on prescribing
  • Market access outlook for emerging therapies

Table of contents

  • Crohn's Disease - Access & Reimbursement - Detailed, Expanded Analysis (EU5)
    • Crohn's Disease - EU5 - Access & Reimbursement - August 2018

Author(s): Anna Reyes, MSc; Kristine Mackin, PhD

Anna Reyes is an analyst on the Global Market Access Insights team at Decision Resources Group, primarily focusing on European market access. She is responsible for monitoring, analyzing, and reporting on global market access through the production of DRG’s Global Market Access Solution (GMAS) and Access & Reimbursement products. Anna’s specific focus is on all aspects of market access in the EU5, as well as in select LatAm countries. Anna holds a bachelor’s degree from the University Rovira i Virgili and a master’s degree in bioengineering from IQS Barcelona.

Kristine Mackin, Ph.D., is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD.

She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her B.A. in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.


Related Reports

Crohn's Disease - Landscape & Forecast - Disease Landscape & Forecast

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. T...

View Details

Crohn's Disease | Disease Landscape and Forecast | G7 | 2020

The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. The well-established TNF-α inhibitors (e.g.,...

View Details